ライフサイエンスコーパス: replication-defective

1 rbor inactivating mutations that render them replication defective.

2 intact genes and regulatory regions but was replication defective.

3 lly, both T125A and T125D mutant viruses are replication defective.

4 All mutant viruses were replication defective.

5 t of the bipartite mutants studied here were replication defective.

6 nd a construct containing both mutations was replication defective.

7 Therefore, viruses with such mutations are replication defective.

8 HR1 cells, the Zta (m22/26,74/75) mutant was replication defective.

9 ant altered at both amino acids 12 and 13 is replication defective.

10 rted into a non-coding region were similarly replication defective.

11 173RR/R157A/R158A are arginine deficient and replication defective.

12 ecific histidine residue at this position is replication defective.

13 More common replication-defective Ad (RD-Ad) vectors with deletions

14 hypothesis that a single administration of a replication-defective Ad gene-transfer vector encoding t

15 the activation of DNA damage responses by a replication-defective Ad vector (AdRSVbetagal) that lack

16 iciency virus type 1 with a regimen in which replication-defective Ad vectors of the human serotype 5

17 In addition, replication-defective Ad vectors that express individual

18 tion of E1A and E1B genes and infection with replication-defective Ad with E1A, E1B, and E3 deleted,

19 mutant Ad5 (Ad5hr) and then immunized with a replication defective Ad5 SIVmac239 Gag/Pol/Nef vaccine

20 alizing antibodies (NAs) to Ad5 who received replication-defective Ad5 (rAd5)-based human immunodefic

21 ssociated Ags (MAAs) by a chimpanzee-derived replication-defective AdC68 vector were compared in a mo

22 This combination of the replication-defective Adeno-P450 with a replication-cond

23 o expand after a booster immunization with a replication-defective adenoviral (Ad) vector also expres

24 zation by priming with DNA and boosting with replication-defective adenoviral (ADV) vectors encoding

25 gated by overexpressing wild-type iex-1 with replication-defective adenoviral gene transfer.

26 To circumvent this problem, a novel replication-defective adenoviral vaccine carrier based o

27 A replication-defective adenoviral vector (Adv) carrying t

28 in an FMD mouse model when delivered with a replication-defective adenoviral vector [Ad5-poIRF7/3(5D

29 ine regimen included a plasmid DNA prime and replication-defective adenoviral vector boost.

30 imal CD8 immunity induced by DNA priming and replication-defective adenoviral vector boosting.

31 processed to single cells, transduced with a replication-defective adenoviral vector encoding GM-CSF,

32 d to single-cell suspension, infected with a replication-defective adenoviral vector encoding GM-CSF,

33 vestigated the combined use of Ad.Egr-TNF, a replication-defective adenoviral vector encoding the cDN

34 Our preclinical and clinical trials using a replication-defective adenoviral vector expressing IFN-b

35 We immunized monkeys with plasmid DNA and replication-defective adenoviral vectors encoding SIV pr

36 al models by gene transfer with the use of a replication defective adenovirus (Ad) containing a human

37 bined with TLR7/8 ligands, then boosted with replication defective adenovirus 5 expressing SIV Gag (r

38 Ectopic expression of mda-7 by means of a replication defective adenovirus results in growth suppr

39 oost regimen with two serologically distinct replication-defective adenovirus (Ad) vectors derived fr

40 lycoproteins encoded by US7 to US10 by using replication-defective adenovirus (Ad) vectors.

41 rtant role for the innate immune response in replication-defective adenovirus (Ad)-mediated acute liv

42 ne tumor vaccine by generating a recombinant replication-defective adenovirus (Ad-HT) that coexpresse

43 Replication-defective adenovirus (ADV) and poxvirus vect

44 elerythrine chloride (10 micromol/L)], and a replication-defective adenovirus (Adv) encoding a domina

45 Replication-defective adenovirus (ADV) vectors represent

46 Here we show that a chimpanzee-derived replication-defective adenovirus (ChAd) vaccine also rap

47 ptosis, when compared with cells infected by replication-defective adenovirus (dl312) as a negative c

48 to systemic viral challenge with recombinant replication-defective adenovirus (rAd).

49 n (HA) and boosting with seasonal vaccine or replication-defective adenovirus 5 vector encoding HA st

50 cell lines U87 and U251 were transduced with replication-defective adenovirus constitutively expressi

51 In the present study we report that a replication-defective adenovirus construct of GMF cDNA (

52 53 protein levels did not change in control, replication-defective adenovirus containing an insertles

53 ed human primary hepatocytes infected with a replication-defective adenovirus containing HBx.

54 Therefore, we constructed a replication-defective adenovirus encoding a GFP-FRNK fus

55 and in combination with immunization using a replication-defective adenovirus encoding h5T4 (Rad.h5T4

56 ility, safety, and transgene expression of a replication-defective adenovirus encoding nitroreductase

57 -induced apoptosis, cells were infected with replication-defective adenovirus expressing either p53 o

58 the efficacy of systemic administration of a replication-defective adenovirus expressing endostatin (

59 analyzed in glioblastoma cells exposed to a replication-defective adenovirus expressing UL82 (Adpp71

60 DN), was introduced into tumor cells using a replication-defective adenovirus expression system.

61 of intrahepatic V(alpha)14iNKT cells during replication-defective adenovirus infection is not known

62 to alleviate liver pathology associated with replication-defective adenovirus infection.

63 The replication-defective adenovirus is a promising vaccine

64 in nonhuman primates by HIV-1 gag-expressing replication-defective adenovirus serotype 5 (Ad5) or pox

65 modified vaccinia virus Ankara vector, and a replication-defective adenovirus serotype 5 (Ad5) vector

66 nd durability of immune responses induced by replication-defective adenovirus serotype 5 (ADV5) vecto

67 Replication-defective adenovirus serotype 5 (rAd5) is th

68 by infecting RA synovial fibroblasts with a replication-defective adenovirus that expresses a consti

69 A control replication-defective adenovirus that expresses beta-gal

70 expression was mediated by infection with a replication-defective adenovirus that expresses Rb (Ad-R

71 s, we cloned BCR(64-413) into a recombinant, replication-defective adenovirus to express useful quant

72 eceiving antiretroviral therapy were given a replication-defective adenovirus type 5 HIV-1 gag vaccin

73 ells after vaccination of female mice with a replication-defective adenovirus vector of human serotyp

74 We used a replication-defective adenovirus vector to deliver the f

75 GFP gene copy number delivered to cells by a replication-defective adenovirus vector, Ad.CMV-GFP, and

76 ent death after hepatic artery infusion of a replication-defective adenovirus vector.

77 Using replication-defective adenovirus vectors and replication

78 product-specific CD8(+) T cells elicited by replication-defective adenovirus vectors are linked to p

79 Here, we show that local delivery of replication-defective adenovirus vectors encoding IL-23

80 To evaluate this, we primed mice with replication-defective adenovirus vectors expressing the

81 Replication-defective adenovirus vectors expressing vIL-

82 vaccines for pathogens for which traditional replication-defective adenovirus vectors have not been e

83 inactivated ORF66 (GFP-66 and GFP-66kd) from replication-defective adenovirus vectors revealed that O

84 To test this hypothesis, replication-defective adenovirus vectors that express wi

85 Replication-defective adenovirus vectors were used to in

86 the UL19 and UL47 genes were expressed from replication-defective adenovirus vectors.

87 of the glycoproteins was expressed by using replication-defective adenovirus vectors.

88 We have made a replication-defective adenovirus, AdCMV-FlagXPA(59-114),

89 e then constructed and generated recombinant replication-defective adenovirus, with DNKu70 controlled

90 es (CpG ODN), and boosted 12 wk later with a replication-defective adenovirus-expressing HIV-Gag (rAD

91 expressed in the RPE of rats by injection of replication-defective adenovirus.

92 d these antigens with plasmid or E1-deleted (replication-defective) adenovirus vectors.

93 Replication defective adenoviruses are promising vectors

94 The innate immune response against replication-defective adenoviruses (Ad) is poorly define

95 iplicity of infection (MOI), 100; 24 h) with replication-defective adenoviruses (Adv) expressing domi

96 Therefore, replication-defective adenoviruses (Advs) encoding const

97 denovirus vaccines that are being tested are replication-defective adenoviruses (RD-Ads).

98 However, broad clinical application of replication-defective adenoviruses in gene therapy is be

99 tive (ad-IGF-1R/dn; 482, 950) are E1-deleted replication-defective adenoviruses.

100 combined with various Th1-type adjuvants and replication-defective alphaviral particles encoding HCV

101 E1 region replacement adenoviruses are replication defective and are propagated in cells provid

102 The LLP-1 mutants (MX1 and MX4) were replication defective and showed an average of 85% decre

103 rmed that HIV-1(V165A) and HIV-1(R166A) were replication defective and that less mutant viral cDNA lo

104 d gene switch, we recently generated a novel replication-defective and anti-HSV-specific HSV-1 recomb

105 ype (WT) reversion during complementation of replication-defective and attenuated viruses via HR with

106 usly constructed a glycoprotein D-expressing replication-defective and dominant-negative HSV-1 recomb

107 B7 costimulation molecules by a prototypical replication-defective antiviral vaccine could enhance im

108 This is the first report of a complete, replication-defective ASLV provirus sequence from any bi

109 evious clinical experience with vaccinia and replication-defective avipox recombinant carcinoembryoni

110 e studies reported here, we demonstrate that replication-defective avipox vectors expressing B7-1 can

111 trol of individual poxvirus promoters, and a replication-defective avipox virus (fowlpox; rF) contain

112 All three mutants are replication defective but produce virus particles.

113 6Q), HIV-1(Q214L/Q216L), and HIV-1(C130G) as replication defective, but phenotypic classification was

114 a formation following infection with a lytic replication-defective BZLF1-deleted (Z-KO) virus or a ly

115 tion of the EBV episome occurred even with a replication-defective BZLF1-knockout virus, amplificatio

116 Replication-defective CAEV proviral constructs lacking t

117 sms contributed to an increased apoptosis of replication-defective cells in the C/EBPbeta-null epithe

118 rtners to accelerate clinical development of replication-defective chimpanzee adenovirus 3 vector vac

119 Specifically, we tested a vaccine based on a replication-defective chimpanzee-derived adenovirus vect

120 nts, which we previously identified as being replication defective, contain abnormally high levels of

121 Replication-defective CR2 point mutants exhibited the sa

122 Three basic viral phenotypes were observed: replication defective (dead; titer < 1 focus-forming uni

123 When ICP4 protein was provided by the replication-defective DNA polymerase mutant HP66, the ge

124 HIV-1 strain carrying K266A/R269A in IN was replication-defective due to a block in reverse transcri

125 an integrase (IN) mutant, which renders HIV replication defective, due to the inability of the provi

126 Adeno-P450, a replication-defective, E1/E3 region-deleted adenovirus e

127 whole Ebola virus (EBOV) vaccine based on a replication-defective EBOV (EBOVDeltaVP30) protects immu

128 type 1 recombinant virus that is completely replication-defective, expresses high-levels of HSV-1 ma

129 Modified vaccinia Ankara (MVA) is a replication defective form of vaccinia virus.

130 at involved vaccinations with the following: replication-defective fowlpox recombinant (rF)-CEA(6D)-T

131 man B cells can be efficiently infected by a replication-defective fowlpox recombinant vector, design

132 Thus, this replication-defective gammaherpesvirus efficiently estab

133 rpesvirus latency, we previously generated a replication-defective gammaHV68 lacking the expression o

134 licating adenovirus to promote the spread of replication-defective gene therapy vectors, such as Aden

135 ne therapy vectors than after injection with replication-defective gene therapy vectors.

136 We examined whether gene transfer with replication-defective genomic herpes simplex virus (HSV)

137 Use of a replication-defective HCV John Cunningham 1/AAG mutant a

138 itic cells (DC) were transduced ex vivo with replication-defective, helper virus-free, herpes simplex

139 silencing in dorsal root ganglia (DRG) using replication-defective herpes simplex viral (HSV-1) vecto

140 Replication-defective herpes simplex virus (HSV) strains

141 e transfer to the dorsal root ganglion using replication-defective herpes simplex virus (HSV)-based v

142 nt study, the effects of gene therapy, using replication-defective herpes simplex virus type 1 (HSV-1

143 nglion neurons transduced with a recombinant replication-defective herpes simplex virus vector coding

144 Subcutaneous inoculation of a replication-defective herpes simplex virus vector expres

145 followed by a subcutaneous inoculation of a replication-defective herpes simplex virus vector expres

146 were inoculated with CVL samples spiked with replication-defective HIV containing a luciferase indica

147 -gamma(+)) cells, even upon infection with a replication-defective HIV vector with a pseudotype envel

148 In contrast, replication-defective HIV-1(E246K) synthesized near-norm

149 could serve as a diagnostic for identifying replication-defective HIV-1.

150 pression in neurons following infection with replication-defective HSV recombinants carrying beta-gal

151 Replication-defective HSV stimulates immune responses in

152 B7 costimulation molecules in a prototypical replication-defective HSV vaccine against HSV-2 genital

153 A replication-defective HSV vector backbone was engineered

154 In animals immunized with replication-defective HSV, durable serum immunoglobulin

155 complement plaque formation in Vero cells by replication-defective HSV-1 strains with mutations in th

156 Immunized mice were inoculated with a replication-defective HSV-1 vector that expressed the Es

157 id of B7-1 and B7-2 costimulation molecules, replication-defective HSV-2 encoding B7-1 or B7-2 induce

158 MPL, gD2 in Freund's adjuvant, and dl5-29 (a replication-defective HSV-2 mutant) in HSV-1-seropositiv

159 s endogenous B7 costimulation molecules with replication-defective HSV-2 or replication-defective vir

160 d a non-gD2-expressing dominant-negative and replication-defective HSV-2 recombinant in protection ag

161 ICP0 null mutant-based dominant-negative and replication-defective HSV-2 recombinant, CJ2-gD2, that c

162 um antibody generated by immunization with a replication-defective HSV-2 vaccine prototype strain in

163 ntrast, B-cell-deficient mice immunized with replication-defective HSV-2 were able to control replica

164 escalation, phase I clinical trial of NP2, a replication-defective HSV-based vector expressing human

165 These results indicate that the ability of a replication-defective HSV-derived vaccine vector to elic

166 and B-cell memory following vaccination with replication-defective HSV.

167 Replication-defective human adenovirus (Ad) group C tran

168 r III interferons (IFNs) by inoculation of a replication-defective human adenovirus 5 (Ad5) vector ex

169 a and type II IFN (IFN-gamma) delivered by a replication-defective human adenovirus 5 (Ad5) vector pr

170 ate with rhesus macaques that priming with a replication-defective human adenovirus serotype 35 (Ad35

171 immunogenicity of formulated plasmid DNA and replication-defective human adenovirus serotype 5 (Ad5)

172 ression of this molecule using a recombinant replication-defective human adenovirus type 5 (Ad5) vect

173 e present study, we constructed recombinant, replication-defective human adenovirus type 5 vectors co

174 I interferon gene (poIFN-alpha/beta) with a replication-defective human adenovirus vector (adenoviru

175 We recently reported a replication-defective human cytomegalovirus with restore

176 nome contains approximately 50 copies of the replication-defective human endogenous retrovirus 9 (ERV

177 emipermeable supports were transduced with a replication-defective human immunodeficiency virus-based

178 genetic immunization of C57BL/6 mice with a replication-defective human papillomavirus pseudovirus (

179 In contrast, F(-) HIV-1(HXBc2) was replication defective in primary T cells.

180 ly as attenuated viruses, are not completely replication defective in vivo.

181 nuclear import may be a common phenotype of replication-defective IN mutant viruses.

182 Further analyses of the replication-defective IN mutants indicated that the bloc

183 ntation of a hyperphosphorylation-deficient, replication-defective JFH1 replicon.

184 nesis, we isolated and characterized a lytic replication-defective KSHV, KV-1, containing an 82-kb ge

185 itro study demonstrates the feasibility of a replication-defective lentiviral vector delivery system

186 tissue and utilized in the construction of a replication-defective lentiviral vector.

187 A replication-defective lentivirus vector that expresses e

188 lication complexes, which were absent when a replication-defective LT mutant or an MCPyV-origin mutan

189 t adenovirus type 5 (rAd5) prime followed by replication-defective lymphocytic choriomeningitis virus

190 echanism to render aptamer-resistant viruses replication defective make this an attractive class of i

191 SV-2 vaccine strain, dl5-29, and other HSV-2 replication-defective mutant strains to protect against

192 However, replication defective mutants failed to unwind a small o

193 Two replication-defective mutants (429DA and 460EA) were gro

194 BMV recombination by expressing a series of replication-defective mutants of BMV RNA3 in (+) or (-)

195 The replication-defective mutants showed defects in both ear

196 Replication-defective mutants were typed as class I (blo

197 Finally, the identification of replication-defective mutants with normal viral assembly

198 e screening method to identify intracellular replication-defective mutants.

199 to facilitate efficient complementation of a replication-defective mutation in NS5A.

200 The replication-defective mutations affected conserved amino

201 ementation assay was also developed in which replication-defective NC mutants were rescued by coexpre

202 to demonstrate intragenic complementation of replication-defective NS5A alleles.

203 his report, we examined an additional set of replication-defective NS5A mutations in trans-complement

204 Replication-defective oncoretroviruses are able to effic

205 ion by codon shuffling as a means to produce replication-defective or attenuated viruses.

206 t viruses were isolated from three different replication-defective parental mutants, and in all cases

207 h the RRR substitution mutation results in a replication-defective phenotype.

208 uck hepatitis virus (WHV) are not completely replication defective, possibly behaving like attenuated

209 We found a replication-defective proviral sequence consisting of pu

210 immunity after replication, oral delivery of replication-defective rAd vectors encoding specific immu

211 followed by a systemic or mucosal boost with replication-defective rAd5-gag.

212 gene transfer and therapy approaches, where replication-defective (RD) gene transfer is required, E1

213 most cases, Ad vaccines are engineered to be replication-defective (RD-Ad) vectors.

214 Replication-defective (RD-Ad6) vectors produce low level

215 cination strategy to administer AERAS-402, a replication-defective recombinant adenovirus (rAd) type

216 or-containing RKO cells were infected with a replication-defective recombinant adenovirus containing

217 afety, tolerability, and immunogenicity of a replication-defective recombinant adenovirus serotype 5

218 one of the following vaccine constructs: (i) replication-defective recombinant adenovirus type 5 (Ad5

219 f ATRA to mice during in vivo priming with a replication-defective recombinant adenovirus vector expr

220 transduction, rats were injected with either replication-defective recombinant adenovirus with DNA co

221 Replication-defective recombinant adenoviruses are the m

222 s, we have generated doxycycline-repressible replication-defective recombinant adenoviruses encoding

223 epatocytes (PRH) or intact male SD rats with replication-defective recombinant adenoviruses encoding

224 A replication-defective recombinant chimpanzee adenovirus

225 CJ9-gD belongs to a new class of replication-defective recombinant herpes simplex viruses

226 les, CJ2-gD2 represents a new class of HSV-2 replication-defective recombinant viral vaccines in prot

227 anisms in intrahepatic immune responses to a replication-defective, recombinant beta-galactosidase-en

228 In replication-defective reporter adenoviruses, the hTR pro

229 oprotein was used successfully to pseudotype replication-defective retroviral and lentiviral vectors

230 nship among MGE-derived interneurons using a replication-defective retroviral library containing a hi

231 gene were produced by injecting pseudotyped replication-defective retroviral vector into the perivit

232 We report, for the first time, a replication-defective retroviral vector-associated neopl

233 oncogene into the mammary epithelium using a replication-defective retroviral vector.

234 We have used replication-defective retroviral vectors to analyze the

235 been widely exploited for the generation of replication-defective retroviral vectors, including thos

236 e bone marrow cells infected in vitro with a replication-defective retrovirus carrying the Sox4 oncog

237 cushion cells responded similarly in vivo, a replication-defective retrovirus encoding FGF-4 with the

238 r investigate these elements, we sequenced a replication-defective retrovirus, here named tetraonine

239 f telencephalic precursors using bicistronic replication defective retroviruses.

240 Chick somitic cells were labeled by using replication-defective retroviruses or quail/chick chimer

241 ses were injected on embryonic day (E)3 with replication-defective retroviruses that express full-len

242 st delamination by labeling progenitors with replication-defective retroviruses.

243 gene expression, these studies have utilized replication-defective retroviruses.

244 ntial for replication of mutant WN RNAs, and replication-defective RNAs failed to produce negative st

245 Studies with replication-defective RNAs suggested that miR-122 did no

246 e NC mutants were rescued by coexpression of replication-defective RT mutants that provided wild-type

247 corresponding hybridoma and inserted into a replication-defective serotype 5 human Ad gene transfer

248 tegies in clinical trials include the use of replication-defective shuttle vectors to deliver exogeno

249 ar stomatitis virus glycoprotein-pseudotyped replication-defective simian immunodeficiency viruses (d

250 n of compounds that inhibit the ability of a replication-defective simian virus 40 (SV40)-based viral

251 Here we used a replication-defective (single-cycle) flavivirus platform

252 We used a helper-free replication-defective SIV macaque (SIVmac)-based retrovi

253 We altered an ICP8(-) replication-defective strain of HSV type 2 (HSV-2), 5Bla

254 gD2, a plasmid expressing gD2, and dl5-29, a replication-defective strain of HSV-2 with the essential

255 igen in mediating priming by pol-prim, three replication-defective T antigens with mutations in the A

256 sed mutational errors that would render them replication defective, these viral RNAs were not differe

257 eripheral blood monocytes were infected with replication-defective type 5 adenovirus.

258 Replication-defective vaccine vectors based on vesicular

259 was detected in 293T cells transfected with replication-defective variants.

260 ther vaccines, including heat-inactivated or replication-defective varicella-zoster virus to prevent

261 itial injection dose), whereas titers of the replication-defective vector decrease rapidly after inje

262 he transgene 3 days after injection with the replication-defective vector, with a rapid decline in ex

263 ant adenoviruses are the most widely studied replication-defective vectors for the potential treatmen

264 , and E1B-19K genes, and adenovirus E1-minus replication-defective vectors that express all E3 genes,

265 classified into those that do not replicate (replication-defective vectors) and those that selectivel

266 ribe a new vaccine candidate that utilizes a replication-defective vesicular stomatitis virus (VSV) v

267 s the persistence of otherwise acute viruses.Replication defective viral genomes (DVGs) can facilitat

268 Replication defective viral genomes (DVGs) generated dur

269 A safe, replication-defective viral vector that can induce mucos

270 . tumors with a replication-conditional or a replication-defective viral vector, each of which expres

271 The inability of replication-defective viral vectors to efficiently trans

272 include peptides, recombinant proteins, DNA, replication-defective viral vectors, genetically disable

273 ed only vertically as proviruses and produce replication-defective virions that package only a portio

274 of HIV that contained the mutations produced replication-defective virions.

275 was performed both in vitro and in vivo with replication-defective virus (DL312) and no treatment as

276 t serum antibody induced by vaccination with replication-defective virus aids in reducing establishme

277 ore IFN-gamma-producing CD4 T cells than did replication-defective virus alone.

278 ainst HSV-2 challenge than immunization with replication-defective virus alone.

279 Prior immunization with B7-expressing, replication-defective virus also effectively suppressed

280 In order to develop a replication-defective virus as a vaccine candidate, we c

281 olecules with replication-defective HSV-2 or replication-defective virus encoding B7-2 and compared t

282 Replication-defective virus encoding B7-2 induced more I

283 ophages purified from mice infected with the replication-defective virus harbored viral genome at a f

284 t replicate and spread in the host, however, replication-defective virus may have relatively limited

285 We have previously shown that replication-defective virus particles are able to induce

286 nt (K30) with two fewer amino acids produced replication-defective virus particles, despite containin

287 lecules, but this signal may be limiting for replication-defective virus vaccines.

288 demonstrated that following vaccination of a replication-defective virus with the restored pentameric

289 Passive transfer of replication-defective virus-immune serum at physiologic

290 vely than did immunization with the parental replication-defective virus.

291 sion of the segment of viral DNA, leading to replication-defective virus.

292 e combined use of intravitreal injections of replication-defective viruses and molecular probes allow

293 ssembly in vivo, we inoculated wild-type and replication-defective viruses into the posterior chamber

294 se the possibility that genetically tailored replication-defective viruses may make effective and saf

295 cted following infection with UV-irradiated, replication-defective viruses possessing transcriptional

296 ility of delivering an antigen and GM-CSF in replication-defective viruses to enhance antigen-specifi

297 otic cellular proteins, exogenous agents, or replication-defective viruses.

298 therefore illustrate that potentially safer replication-defective VSV can be successfully engineered

299 These replication-defective VSV vectors were effective at gene

300 e gD in infected cells, CJ9-gD is completely replication defective, yields high-level expression of g